Yellow Fever Treatment Market Size and Share - Growth Analysis Report and Forecast Trends 2026-2030

The global yellow fever treatment market is valued at approximately $571 million in 2026, representing continued expansion from an estimated $525 million in 2024. Growth is driven by rising disease burden in endemic regions, expanding vaccination campaigns, and growing travel immunization requirements. The market encompasses the primary live-attenuated vaccine as well as supportive care regimens for confirmed infections.

• •Market projected to reach approximately $664 million by 2030 at a 3.9% CAGR
• •Disease endemicity concentrated in roughly 40 countries across tropical Africa and South America
• •Vaccination serves as the primary and most effective preventive and therapeutic intervention

Recurring and expanding yellow fever outbreaks in endemic regions, particularly in sub-Saharan Africa and South America, have heightened public health urgency and increased demand for vaccines and treatment protocols. International travel requirements mandating yellow fever vaccination certificates for entry into affected countries further stimulate market demand. Ongoing support from global health agencies and expanding immunization programs in at-risk nations continue to underpin sustained market expansion.

• •Outbreak recurrence in tropical Africa and South America elevates public health response funding
• •International Certificate of Vaccination requirements drive demand from international travelers
• •Expanded routine immunization programs in endemic nations supported by multilateral health partnerships

The market is predominantly segmented by product type, with live-attenuated vaccines representing the largest and most critical component alongside supportive treatment products for acute infection management. Geographically, the market is concentrated in endemic regions of sub-Saharan Africa and South America, with Brazil representing a significant national market following notable outbreak activity. Demand in non-endemic regions is largely driven by travel-related immunization needs and national stockpiling by health authorities.

• •Vaccine segment dominates market share as the primary preventive and therapeutic modality
• •Brazil and broader South America represent major regional demand centers
• •African markets exhibit the highest disease burden and corresponding treatment demand

Who are the notable companies in the industry?

The yellow fever treatment market is characterized by moderate consolidation, with a limited number of established producers supplying the majority of global demand through long-standing manufacturing capabilities. Production is largely integrated within broader vaccine portfolios rather than operated by narrow-specialty manufacturers, leveraging decades of established cell-culture and fermentation expertise. Manufacturing capacity is concentrated in a handful of regions with deep regulatory experience in vaccine production, creating a supply structure that is highly dependent on a small number of qualified facilities worldwide.

• •Supply chain moderately consolidated with few qualified global manufacturers
• •Production relies on established egg-based and cell-culture vaccine manufacturing routes
• •Regulatory qualification requirements create high barriers to entry, limiting new market participants

What are the recent trends and outlook?

The market is expected to maintain steady growth through 2030, underpinned by continued vaccination program expansion, periodic outbreak-driven demand surges, and growing requirements for travel-related immunization. Advances in vaccine thermostability and improved cold-chain logistics are expected to broaden access in remote endemic regions. Long-term market evolution may be influenced by pipeline candidates exploring next-generation vaccine formulations and antiviral therapies currently in development.

• •Steady 3.9% CAGR expected through 2030, reaching approximately $664 million
• •Vaccine thermostability improvements and cold-chain innovations to expand geographic reach
• •Pipeline development of antiviral candidates and improved vaccine formulations anticipated